← All stocks

Neumora Therapeutics, Inc.

NMRA Scheduled selling only

CIK 0001885522 #3643 in the set updated 18 Sep 2026

Bought (1 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (1 mo)

$481.51K

$0.00 on a plan · $481.51K straight out of an exercise

Sold at will

$0.00

0 of 8 sales

Net

−$481.51K

$0.00 against sales at will

By person

9 insiders · 8 transactions

16.8×

Paul L. Berns holds 16.8 times base salary in stock. $11.80M of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Paul L. Berns last reported holding, valued at $1.60, the price Common Stock was last bought or sold at on the open market here, on 21 Aug 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Aurora Daljit Singh

See Remarks

—

$481.51K (8) scheduled

−$481.51K

48,750

0.0259%

$77.80K

−77.0%

BERNS PAUL L

See Remarks

—

7,395,185

3.94%

$11.80M

−5.4%

Burow Kristina

Director

—

6,046,907

3.22%

$9.65M

+46.4%

ARCH Venture Partners XII, LLC entity

10% owner

—

6,046,907

3.22%

$9.65M

+46.4%

ARCH Venture Partners X, LLC entity

10% owner

—

6,046,907

3.22%

$9.65M

+46.4%

Lenz Robert A.

Head of R&D

—

309,092

0.1645%

$493.25K

−8.9%

Pinto Joshua

President & CEO

—

209,950

0.1117%

$335.04K

−6.3%

Milligan Michael Lee

See Remarks

—

21,034

0.0112%

$33.57K

−14.0%

Fust Matthew K

Director

—

20,100

0.0107%

$32.08K

0.0%

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 6

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 8

Sales at will 0

Transactions with no price 0

Shares from compensation/vesting 307,127

History held since 18 Sep 2023